tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Plus Therapeutics Enters Purchase Agreement with Lincoln Park

Story Highlights
Plus Therapeutics Enters Purchase Agreement with Lincoln Park

Elevate Your Investing Strategy:

The latest update is out from Plus Therapeutics ( (PSTV) ).

Plus Therapeutics has entered into a Purchase Agreement with Lincoln Park, which is an accredited investor, to issue and sell securities under exemptions from the registration requirements of the Securities Act. This strategic move allows Plus Therapeutics to raise capital while leveraging regulatory exemptions, potentially impacting its financial strategy and stakeholder interests.

The most recent analyst rating on (PSTV) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.

Spark’s Take on PSTV Stock

According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.

The stock of Plus Therapeutics is significantly hindered by its poor financial performance and challenging valuation. The technical analysis further supports a bearish outlook. While the earnings call offers some positive clinical and financial developments, these are overshadowed by ongoing financial and regulatory difficulties, including potential Nasdaq delisting.

To see Spark’s full report on PSTV stock, click here.

More about Plus Therapeutics

Average Trading Volume: 7,753,313

Technical Sentiment Signal: Sell

Current Market Cap: $6.63M

See more data about PSTV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1